A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Denise C. Hsu; Kimberly F. Faldetta; Luxin Pei; Virginia Sheikh; Netanya S. Utay; Gregg Roby; Adam Rupert; Anthony S. Fauci; Irini Sereti

doi:10.1093/cid/civ841

A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Denise C. Hsu, Kimberly F. Faldetta, Luxin Pei, Virginia Sheikh, Netanya S. Utay, Gregg Roby, Adam Rupert, Anthony S. Fauci, Irini Sereti

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

Original language	English (US)
Pages (from-to)	258-261
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	62
Issue number	2
DOIs	https://doi.org/10.1093/cid/civ841
State	Published - Jan 15 2016
Externally published	Yes

Keywords

immune reconstitution inflammatory syndrome
infliximab
mycobacterial infection

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/civ841

Cite this

@article{7d47e1826fbf413490da667ce88ea0b6,

title = "A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS",

abstract = "The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.",

keywords = "immune reconstitution inflammatory syndrome, infliximab, mycobacterial infection",

author = "Hsu, {Denise C.} and Faldetta, {Kimberly F.} and Luxin Pei and Virginia Sheikh and Utay, {Netanya S.} and Gregg Roby and Adam Rupert and Fauci, {Anthony S.} and Irini Sereti",

note = "Publisher Copyright: {\textcopyright} 2015 Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.",

year = "2016",

month = jan,

day = "15",

doi = "10.1093/cid/civ841",

language = "English (US)",

volume = "62",

pages = "258--261",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - A Paradoxical Treatment for a Paradoxical Condition

T2 - Infliximab Use in Three Cases of Mycobacterial IRIS

AU - Hsu, Denise C.

AU - Faldetta, Kimberly F.

AU - Pei, Luxin

AU - Sheikh, Virginia

AU - Utay, Netanya S.

AU - Roby, Gregg

AU - Rupert, Adam

AU - Fauci, Anthony S.

AU - Sereti, Irini

N1 - Publisher Copyright: © 2015 Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PY - 2016/1/15

Y1 - 2016/1/15

N2 - The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

AB - The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

KW - immune reconstitution inflammatory syndrome

KW - infliximab

KW - mycobacterial infection

UR - http://www.scopus.com/inward/record.url?scp=84960172014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960172014&partnerID=8YFLogxK

U2 - 10.1093/cid/civ841

DO - 10.1093/cid/civ841

M3 - Article

C2 - 26394669

AN - SCOPUS:84960172014

SN - 1058-4838

VL - 62

SP - 258

EP - 261

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this